Special Issue

Topic: Targeting Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Guest Editor(s)
Special Issue Introduction
Resistance to therapy is major challenge of the clinical management of cancer patients. Recent approaches have shown how intra-tumoral heterogeneity (ITH) is a major propeller of drug resistance, because of the clonal evolution and the consequent broad spectrum of stress- adaptive mechanisms set in place in therapy-challenged tumors. Omics approaches, including transcriptomic, genomic, proteomics and metabolomics analysis and targeted at both cancer cells and tumor microenvironment, are expected to greatly contribute knowledge of resistance mechanisms to overcome such a challenge. Another critical point is the choice of relevant sources and experimental settings to study resistance to therapy. This broadly covers in vitro cell culturing up to 3D cultures and organoids, with the last two holding more promise due to the ability to keep a more intact genetic makeup of the originating specimen. Current efforts to overcome cancer drug resistance do need to consider, on one hand, the high need for novel agents and, on the other hand, potential for drug repositioning and sequencing of treatments. This requires a tighter than ever interaction between basic, translational and clinical scientist and to this interdisciplinary audience is devoted this Special Issue of Cancer Drug Resistance.
Keywords
Signaling pathways, targeted therapies, single-cell biology, nanomedicines, precision oncology, omics, drug resistance, cancer stem cells, epithelial mesenchymal transition, metabolism, tumor microenvironment
Submission Deadline
31 Mar 2022
Submission Information
For Author Instructions, please refer to https://oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=841
Submission Deadline: 31 Mar 2022
Contacts: Bella Zhao, Assistant Editor, bella@cdrjournal.com
Published Articles
Open Access Review
Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapy
This article belongs to the Special Issue Targeting Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Cancer Drug Resist 2023;6:447-67.
DOI: 10.20517/cdr.2023.21
Available online: 12 Jul 2023
Open Access Review
Aberrant Notch signaling in gliomas: a potential landscape of actionable converging targets for combination approach in therapies resistance
This article belongs to the Special Issue Targeting Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Cancer Drug Resist 2022;5:939-53.
DOI: 10.20517/cdr.2022.46
Available online: 17 Oct 2022
Open Access Original Article
Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells
This article belongs to the Special Issue Targeting Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Cancer Drug Resist 2022;5:814-28.
DOI: 10.20517/cdr.2022.56
Available online: 2 Jul 2022
Open Access Original Article
Electrochemotherapy using thin-needle electrode improves recovery in feline nasal planum squamous cell carcinoma - a translational model
This article belongs to the Special Issue Targeting Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Cancer Drug Resist 2022;5:595-611.
DOI: 10.20517/cdr.2022.24
Available online: 20 Jun 2022